Moderna, Inc. vs Utilities Select Sector SPDR Fund — how do they compare? Moderna, Inc. trades at $135.95 (market cap $56.02B), while Utilities Select Sector SPDR Fund trades at $42.95. The key difference: Moderna, Inc. is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| MRNA | XLU | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | — |
52-Week High | $174.38 | $47.73 |
52-Week Low | $22.36 | $41.86 |
Enterprise Value | $52.17B | — |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
XLU trades at $43.45, up 0.86% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The utilities ETF faces conflicting narratives around AI power demand versus regulatory headwinds, with recent news highlighting both defensive appeal and concerns about concentrated AI exposure. Support levels cluster around $42-43 while resistance sits at $44.
The ETF's outlook balances defensive utility characteristics against AI-driven growth potential. Key opportunities include inflation hedging and dividend income, while risks center on regulatory intervention and uneven AI benefits across the portfolio. Current sentiment reflects cautious optimism as investors weigh utility stability against transformative power demand.
Trailing returns across standard periods
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →